CB21 Pharma, the spin-off sister company to CBDepot, successfully extends EU GMP certification to broaden its cannabis-derived active pharmaceutical ingredients (API) portfolio.

CB21 Pharma, a leading Czech-based pharmaceutical company specializing in producing cannabinoid ingredients and medical devices, has successfully extended its EU Good Manufacturing Practice (GMP) certification under certificate # sukls105303/2023. This achievement allows CB21 Pharma, the spin-off sister company to pioneering CBDepot, to continue manufacturing Active Pharmaceutical Ingredients (APIs) such as Cannabidiol (CBD), from initial extraction to the production of full spectrum distilled and standardized extracts from medicinal cannabis, marketed as Cannabis Extractum Raffinatum and Cannabis Extractum Normatum.
CBDepot

-
SK
-
2017On CPHI since
-
2Certificates
-
25 - 49Employees
Other Content from CBDepot (1)
-
News CBDepot launches the sale of synthesized pharma-grade CBD
CBDepot group starts the marketing of synthesized pharma-grade CBD produced under the EU GMP umbrella of its sister company CB21 Pharma, s.r.o.